Artelo Targets FABP5 to Treat Chemo Nerve Pain
PRESENTER: Andrew Yates, Chief Scientific Officer of Artelo Biosciences This video will be available from November 9, 2026 - May 9, 2027 TRANSCRIPT Afternoon, everyone. My name is Andrew Yates. I'm the chief scientific officer of Artelo Biosciences. Artelo is a Anglo American company headquartered out in San Diego, USA with listing on the Nasdaq with the the ticker ARTL. And I represent the UK r and d function, which is headquartered in Manchester, UK. And our mission is developing science that modifies lipids to help patients with great unmet need. And we primarily got into this because we all have a strong background in endocannabinoid science. Endocannabinoids, as you know, are lipids. And as we've embarked upon our research over the last nine years, we've we've developed more and more understanding that we modify much more than just the endocannabinoid system. As we are a Nasdaq listed company, I'm gonna represent views of the management and the board today that our estimates of the future and our full disclosures are available on our website, artello.com. We're a clinical, biotech, with two compounds in the clinic. And before I go into the details on the medicine I'll spend most of the time talking about today, ART2612, I just wanted to give you a high level view of the entire portfolio. So we have a dual cannabinoid receptor agonist, which has been peripherally restricted so that doesn't get into the brain, is being trialed in cancer related anorexia and in glaucoma, both in phase two studies. The anorexia study called Cares, has completed, and we shared that data which showed that the compound was able to produce weight increases, muscle increases, and activity increases in patients with cancer versus placebo. And the glaucoma study is an ISS that's going on at the moment in Belfast, Northern Ireland, which is evaluating the lowering of intraocular pressure using our orally available cannabinoid, in patients with early diagnosed glaucoma. ART2612 represents a novel target targeting FABP five and we'll spend the rest of the presentation talking about that and its primary indication is in chemotherapy induced peripheral neuropathy and expanding beyond that into other peripheral neuropathies and osteoarthritis. And we have a compound that is in IND or the European equivalent of development, which is a co crystal, a fully patented co crystal of CBD, which is being developed in generalized anxiety disorder and depression based on fantastic preclinical results, which showed equivalence to sertraline and also equivalence to just, sorry, improved performance against CBD. And if anyone wanted to talk to me about any of those programs, please feel free to meet me afterwards. But let's get into the program that I wanted to spend the majority of my talk telling you about, which is fatty acid binding protein. What are FABPs? They're internal or intracellular chaperone proteins that interact with the cellular membrane to transport lipids from the membrane and the extracellular space inside the cell and ultimately to their fate within the cell be that lipid storage, lipid metabolism, cell signaling through the nucleus, or a number of different transcriptions that can occur at the various sites within the cell. There are nine of them expressed in humans, and we are interested primarily in FABP five that has the greatest affinity for the endocannabinoids such as anandamide. That's what got us first interested in this program. FABP five is a novel target in pain, so it doesn't sit on many pharmaceutical companies' wish list right now, and that's because we haven't validated this data fully in in humans with our forthcoming clinical trial. But the evidence is strong that this has a essential role, particularly in peripheral neuropathy and also in osteoarthritis. And this is some data that just shows that if you take the DRG, the dorsal root ganglia, and extract it, you find in about a third of the neurons high expressions of FABP five. And where you find FABP five, it's actually co located to... With the well known pain receptor, TRPV one, and that's given us some clues that the target is present in the right tissues and the target is associated with known pain receptors. A series of work at laboratories independent of our own has shown that if you knock down or knock out the FABP five protein either at the whole animal or the tissue level, you always produce analgesic or antiallergenic effects in those animals. And those effects are associated with increases in analgesic endo... Endogenous lipids or a reduction in inflammatory and cytokine lipids. Our lead inhibitor is being targeted in chemotherapy induced peripheral neuropathy. So work by different groups has shown that patients with cancer, all cancers can end up with about forty percent of them have, peripheral neuropathy that can either be during their treatment and or can persist beyond treatment. But with some particular chemotherapies such as oxaliplatin, that rate can increase to ninety percent. So that's patients who take a therapy to cure their cancer or or reduce their cancer, and ultimately, ninety percent of them will end up with very, life affecting changes to their peripheral neuropathy and also, lead to dose reductions and reductions in the time on treatment, so ultimately affecting their cancer care. This is three pieces of evidence from our, preclinical work. So all of these were done in rodents where the rodents were, given peripheral neuropathy by the induction of oxaliplatin. In the first panel, you see that the PDP k effects of our drug, with the orange line indicating the PK exposure in plasma and the blue line representing a pain endpoint, in this case, poor withdrawal threshold. What I want you to notice that the pain effects outlast the pharmacokinetic, exposure of the drug. In the second panel, we're looking here at an induced neuropathy, which we then, treat with ART twenty six twelve. And the shaded blue bars are where we use antagonists against known, receptor systems that we're interested in. And in the final collection of bars that you can see that the effect of a r t twenty six twelve is affected by antagonism of c b one, c b two, TRPV one, and PPAR alpha receptors, which shows us that the, downstream biology is very broad and hitting a number of different pharmaceutical, known pain targets. In the final, panel, we're showing that with an induced neuropathy caused by oxaliplatin, we can achieve, reduction in pain equivalent to pregabalin, on day 14. But the animals, in our case, treated with twenty six twelve were not sedated, were normal, went about their business. Those on pregabalin, of course, were quite heavily sedated with that dose of drug, and not as responsive. We've also done some work in the, surgical destabilization of the medial meniscus, which is a robust model for osteoarthritis, again in rodents. And again, panel one here is showing that you have an acute effect given on day one after the, surgery has been allowed to develop. So we actually left the surgical model to mature for three months, which actually is a very severe model of osteoarthritis. And on day one, we gave our treatments and it was equivalent in its efficacy to the dose of naproxen. And the middle bar shows that that that pain relief was was maintained over four weeks So the the the the didn't diminish, and held its own against naproxen at four weeks. What we did after the animals were terminated, we looked at the stomach mucosa and found significantly more lesions in the animals that were treated with naproxen than we did in the animals treated with ART twenty six twelve. The way we work is that we talk... We are very selective towards our target, which is shown on the left here with our small molecule inhibitor interacting with the protein. We have very few off target effects and is selective to the FABP isoform number five. What we have monitored throughout all of our preclinical work is an increase in known, lipids that interact with pain receptor systems, and you can see them here in this chart, which ultimately produce the analgesia. So I like to think of this in terms of... If you were to talk about this in a military term, at the beginning as a sniper, very focused, very precise, very accurate hitting the target. Once the target's engaged, the downstream biology is more like a shotgun and has a very broad reach. All of our work is published in peer reviewed papers, and we've shown our effects in not just oxaliplatin induced peripheral neuropathy, but also paclitaxel induced peripheral neuropathy, diabetic neuropathy and cancer bone pain induced neuropathy as well as the osteoarthritis data. So a very strong preclinical package. As it's a new target, want to re examine the safety of the target. Our group published peer reviewed literature that showed in over 300, examples where they use knockdown, knockout, pharmacological inhibition, or human genetic mutations or snips. There was no concern around safety or toxicology in any of those models. We also, in our own, program, showed that we had a no observed effect level of the highest ICH levels that we're expected to go to of one gram per kilogram per day. So each animal was given a large amount of compound for thirty five days. And indeed, in one experiment, we went even higher up to two grams per kilogram per day. And you'll see on our next slide in the in the clinic, we showed no adverse effects in our single ascending dose study. This data is also published and is available for review. And finally, we are in our single ascend... Sorry. We've completed our single ascending dose study, and we are starting our multiple ascending dose study by year end and expect results expected in quarter two next year. And I want you to note here that we had really nice linear PK up to nine hundred milligrams of single dose of ART2612. You can see here by the arrow... Orange arrow that we have a large therapeutic window based on translation from the animal models. Giving us an indication of somewhere around two hundred milligrams as an active dose. And we also examined our metabolite profiles. We have less than 5% metabolite. So we're talking about dealing with the parent molecules, PK and PD effects. And we believe we've identified a collection of biomarkers that we can use in the MAD study to track target engagement. So you can imagine by knocking this target or inhibiting this target, you change the lipidome and protein profile, and that's what we're looking at as a biomarker suite to track target engagement in our multiple ascending dose study. FABP five is a wonderful target. It's one of the most interesting targets I've worked on in my pharmaceutical career. And with the drug ART twenty six twelve, we've actually shown effects in psoriasis models, in cancer models, and in anxiety models. And our plan for targeting these is to use the library of compounds built on the same scaffold as a r t twenty six twelve, but develop unique chemical entities as candidate drugs against all of those different indications. So a r t twenty six twelve will solely be developed in pain, but there are other molecules in our portfolio that will be developed for the dermatology, cancer, and anxiety applications. Finally, it's a sort of a a thank you to the wider team. Our board is, people who know what good and finish looks like in the pharmaceutical pharmaceutical business, and they're guiding us at every step. The management team here, some of you may know if you've worked in cannabinoids, Saoirse O'Sullivan, who has been a professor in that field for over twenty years and now works for Artelo. And I think most exciting for us is that the innovators and discoverers of FABP five are based in Stony Brook University in The US, and you can see that two of their, academic staff remain on our scientific advisory board working step... Hand in glove with us at every step to develop this program. So I'd like to thank you for your time listening to me today. And my buffer. I can't actually activate the slides, and it locks you out. But, yeah, if you wanna... If you are interested at all, come and see me afterwards or contact us on [email protected] . That's [email protected] . Thank you.